Characteristics of studies included in the metaanalysis. Values are % unless otherwise specified.
| Articles | BMI, kg/m2 | n (%) | Age, Yrs, Mean ± SD | Women | RA Duration, Mean ± SD or Median (IQR) | Smoking Ever | RF Positivity | Anti-CCP Positivity | Treatment Use | |
|---|---|---|---|---|---|---|---|---|---|---|
| GC | DMARD | |||||||||
| Ajeganova, et al33 | 20–24.99 | 775 (48.5) | 53.9 ± 15.4 | 71.4 | ≤ 1 yrs | 55.8 | 62.2 | NA | 36.7 | 77.9 |
| ≥ 30 | 206 (12.9) | 57.9 ± 12.2 | 68.4 | ≤ 1 yrs | 59 | 61.9 | NA | 30.9 | 84.9 | |
| Baker, et al31 | 20–24.9 | 156 (31.2) | 47.6 ± 13.6 | 85.9 | 1.15 (0.6–4.4) yrs | 28.9 | 78.1 | 78.1 | 54.5 | NA |
| ≥ 30 | 127 (25.5) | 50.8 ± 11.7 | 82.7 | 1.3 (0.5–3.3) yrs | 39.8 | 63.8 | 62.5 | 54.7 | NA | |
| Brown, et al34 | 18.5–24.99 | 65 (38.7) | 63.5 ± 12.3 | 75.4 | 17.35 ± 10.1 mos | NA | NA | NA | 26.7 | 75.4 |
| > 30 | 44 (26.2) | 63.2 ± 9.1 | 72.7 | 15.8 ± 8.1 mos | NA | NA | NA | 29.5 | 68.2 | |
| Straburzyńska-Lupa, et al32 | 18.5–24.9 | 19 (37.3) | 55.6 ± 4.5 | 100 | 11.9 ± 6.6 yrs | NA | 72.7 | NA | 77.3 | 95.5 |
| > 30 | 22 (32.2) | 57.5 ± 4.29 | 100 | 11.3 ± 7.1 yrs | NA | 84.2 | NA | 57.9 | 94.7 | |
| Tekaya, et al25 | < 25 | 43 (36.1) | 51.0 ± 12.6 | 77 | 15.5 ± 12.3 yrs | NA | 68.9 | 56.3 | NA | NA |
| ≥ 30 | 36 (30.3) | |||||||||
| Van der Helm-van Mil, et al, EAC29 | < 25 | 156 (47) | 54.5 ± 17.1 | 74 | 8 yrs | 42 | NA | 51 | NA | NA |
| ≥ 30 | 30 (9) | 55.4 ± 13.5 | 67 | 30 | 50 | |||||
| BeST29 | < 25 | 110 (44.5) | 53.1 ± 14.7 | 76 | 25 (15–45) weeks | 41 | NA | 66 | NA | NA |
| ≥ 30 | 36 (14.6) | 54.2 ± 10.4 | 86 | 31 | 59 | |||||
| Westhoff, et al30 | < 25 | 303 (39.5) | 54.9 ± 13 | 71.9 | 12.3 ± 7 mos | NA | 64.4 | NA | NA | 93.6 |
| ≥ 30 | 149 (19.4) | 58.7 ± 12 | 82.6 | 11.0 ± 7 mos | NA | 55.7 | NA | NA | 95.4 | |
BMI: body mass index; RA: rheumatoid arthritis; IQR: interquartile range; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; GC: glucocorticoids; DMARD: disease-modifying antirheumatic drugs; EAC: Early Arthritis Clinic; BeST: Behandel Strategieën, i.e., Treatment Strategies Study; NA: not applicable.